Vaxart doses first patient in 10,000-subject Phase 2b oral COVID-19 vaccine trial against mRNA comparator

Vaxart, Inc.

First patient dosed in 10,000-participant portion of Phase 2b trial for oral pill COVID-19 vaccine candidate.
Trial to assess relative efficacy, safety, and immunogenicity versus approved mRNA COVID-19 vaccine over 12 months.
DSMB reviewed 400-participant sentinel cohort safety data and recommended study proceed without modifications.
Project funded by BARDA/NIAID under Project NextGen with award valued up to $460.7 million.

item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.